Islet cell autoantibodies in patients younger than 20?years of age with recently diagnosed diabetes in Northwest of Iran

详细信息    查看全文

• 作者：Leili Yazdchi Marandi (1)
  Mehrangiz Rajaii (1)
  Akbar Aliasgarzadeh (2)
  Homayoun Sadeghi-Bazargani (3) (4)
  
• 关键词：Type 1 diabetes mellitus ; Anti ; GAD65 autoantibodies ; Anti ; ICA ; C ; peptide
• 刊名：International Journal of Diabetes in Developing Countries
• 出版年：2011
• 出版时间：April 2011
• 年：2011
• 卷：31
• 期：2
• 页码：70-75
• 全文大小：122KB
• 参考文献：1. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2001;358:221-. CrossRef
  2. Kobayashi T, Tamemoto K, Nakanishi K. Immunogenetic and clinical characterization of slowly progressive IDDM. Diab Care. 1993;16:780-. CrossRef
  3. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, et al. Identification of the 64?K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature. 1990;347:151-. CrossRef
  4. Winter WE, Harris N, Schatz D. Type 1 diabetes islet autoantibody markers. Diab Technol Ther. 2002;4:817-9. CrossRef
  5. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diab Care. 2003;26 Suppl 1:S5-0.
  6. Bingley PJ, Bonifacio E, Williams AJ, Genovese S, Bottazzo GF, Gale EA. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes. 1997;46:1701-0. CrossRef
  7. Gorus FK, Goubert P, Semakula C, Vandewalle CL, De Schepper J, Scheen A, et al. IA-2- autoantibodies complement GAD65-autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblings. The Belgian diabetes registry. Diabetologia. 1997;40:95-. CrossRef
  8. Hagopian WA, Sanjeevi CB, Kockum I, Landin-Olsson M, Karlsen AE, Sundkvist G, et al. Glutamate decarboxylase-, insulin- and islet cell-antibodies and HLA typing to detect diabetes in a general population-based study of Swedish children. J Clin Invest. 1995;95:1501-1. CrossRef
  9. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK prospective diabetes study group. Lancet. 1997;350:1288-3. CrossRef
  10. Van Deutekom AW, Heine RJ, Simsek S. The islet autoantibody titres: their clinical relevance in latent autoimmune diabetes in adults (LADA) and the classification of diabetes mellitus. Diabet Med. 2008;25:117-5. CrossRef
  11. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-3. CrossRef
  12. Unnikrishnan AG, Bhatia E, Bhatia V, Bhadada SK, Sahay RK, Kannan A, et al. Type 1 diabetes versus type 2 diabetes with onset in persons younger than 20?years of age. Ann NY Acad Sci. 2008;1150:239-4. CrossRef
  13. Damanhouri LH, Dromey JA, Christie MR, Nasrat HA, Ardawi MS, Robins RA, et al. Autoantibodies to GAD and IA-2 in Saudi Arabian diabetic patients. Diabet Med. 2005;22:448-2. CrossRef
  14. Wan Nazaimoon WM, Faridah I, Singaraveloo M, Ismail IS, Wan Mohamad WB, Letchuman R, et al. Prevalence of glutamic acid decarboxylase antibodies amongst young Malaysian diabetics. ; 1999;43:59-6.
  15. Lutale JJK, Thordarson H, Holm PJ, Eide GE, Vetvik K. Islet cell autoantibodies in African patients with type 1 and type 2 diabetes in Dar es Salaam Tanzania: a cross sectional study. J Autoimmune Dis. 2007;4:4-0. CrossRef
  16. Taplin CE, Barker JM. Autoantibodies in type 1 diabetes. Autoimmunity. 2008;41:11-. CrossRef
  17. Imagawa A, Itoh N, Hanafusa T, Katsura H, Yamaguchi A, Takeda A, et al. High prevalence of antibodies to glutamic acid decarboxylase in comparison to islet cell antibodies in patients with long-standing insulin-dependent diabetes mellitus. Res Commun Mol Pathol Pharmacol. 1996;92:43-2.
  18. Kupila A, Muona P, Simell T, Arvilommi P, Savolainen H, Hamalainen AM, et al. Feasibility of genetic and immunological prediction of type I diabetes in a population-based birth cohort. Diabetologia. 2001;44:290-. CrossRef
  19. Niskanen LK, Tuomi T, Karjalainen J, Groop LC, Uusitupa MI. GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis. Diab Care. 1995;18:1557-5. CrossRef
  20. Tung YC, Chen MH, Lee CT, Tsai WY. β-cell autoantibodies and their function in Taiwanese children with type 1 diabetes mellitus. J Formos Med Assoc. 2009;108:856-1. CrossRef
  21. Notsu K, Oka N, Note S, Nabeya N, Kuno S, Sakurami T. Islet cell antibodies in the Japanese population and subjects with type 1 (insulin-dependent) diabetes. Diabetologia. 1985;28:660-. CrossRef
  22. Park Y, EIisenbarth GS. Genetic susceptibility factors of type 1 diabetes in Asians and their functional evaluation. Diab Metab Res Rev. 2001;17:2-1. CrossRef
  23. Park Y, Lee H, Takino H, Abiru N, Kawasaki E, Eisenbarth GS. Evaluation of the efficacy of multiple autoantibody screening in Korean patients with IDDM. Acta Diabetol. 2001;38:51-6. CrossRef
  24. Omar MA, Bottazzo G, Asmal AC. Islet cell antibodies and other autoantibodies in South African blacks and Indians with insulin dependent diabetes mellitus (IDDM). Horm Metab Res. 1986;18:126-. CrossRef
  25. Peters WH, Lester FT, Kohnert KD, Hildmann W. The frequency of islet cell surface antibodies in newly diagnosed diabetics from Ethiopia. Exp Clin Endocrinol. 1986;87:326-2. CrossRef
  26. Panz VR, Kalk WJ, Zouvanis M, Joffe BI. Distribution of autoantibodies to glutamic acid decarboxylase across the spectrum of diabetes mellitus seen in South Africa. Diabet Med. 2000;17:524-. CrossRef
  27. Thunander M, Petersson C, Jonzon K, Fornander J, Ossiansson B, Torn C, et al. Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden. Diab Res Clin Pract. 2008;82:247-5. CrossRef
  28. Rapaport R, Silverstein JH, Garzarella L, Rosenbloom AL. Type 1 and type 2 diabetes mellitus in childhood in the United States: practice patterns by pediatric endocrinologists. J Pediatr Endocrinol Metab. 2004;17:871-. CrossRef
  29. Pozzilli P, Guglielmi C, Pronina E, Petraikina E. Double or hybrid diabetes associated with an increase in type 1 and type 2 diabetes in children and youths. Pediatr Diab. 2007;9:88-5. CrossRef
  30. Wei Z, Wang K, Qu HQ, Zhang H, Bradfield J, Kim C, et al. From disease association to risk assessment: an optimistic view from genome-wide association studies on type 1 diabetes. PLoS Genet. 2009;5:1-1.
  31. Aly TA, Ide A, Jahromi MM, Barker JM, Fernando MS, Babu SR, et al. Extreme genetic risk for type 1A diabetes. PNAS. 2006;103:14074-. CrossRef
  32. Permutt MA, Wasson J, Cox N. Genetic epidemiology of diabetes. J Clin Invest. 2005;115:1431-. CrossRef
  33. Gao P, Jiao Y, Xiong Q, Wang CY, Gerling I, Gu W. Genetic and molecular basis of QTL of diabetes in mouse: genes and polymorphisms. Curr Genomics. 2008;9:324-. CrossRef
  
• 作者单位：Leili Yazdchi Marandi (1)
  Mehrangiz Rajaii (1)
  Akbar Aliasgarzadeh (2)
  Homayoun Sadeghi-Bazargani (3) (4)
  
  1. Immunology Department, Faculty of Medicine, Tabriz University of Medical Sciences, Golgasht Ave, Tabriz, Iran
  2. Endocrinology Department, Emam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran
  3. PHS Department, Karolinska Institute, Stokholm, Sweden
  4. Research Development Center, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
  

文摘

The presence or absence of islet cell autoantibodies is one of the most direct ways to distinguish between type 1 and 2 diabetic patients. The objective of the present study was to assess the prevalence of β-cell autoantibodies such as glutamic acid decarboxylase-65 antibodies (GADAs) and islet cell antibodies (ICA) among patients younger than 20?years of age with recently diagnosed diabetes in northwest of Iran. From 2006 to 2008, 163 patients were enrolled in this study. They were clinically classified into two groups: 136 with type 1 diabetes (T1D) and 27 with type 2 diabetes (T2D). Serum levels of GADAs, ICA and C-peptide were determined with enzyme linked immunosorbent assay (ELISA) kits. Fasting blood glucose and HbA1c levels were also determined. Chi-square test, independent t test and one-way analysis of variance were used for data analysis. The prevalence of GADAs in T1D patients was 33.1%, slightly lower than that of ICA 35.3%. Forty-eight patients (35.3%) with T1D were positive for ICA compared to only one (3.7%) in T2D patients. The overall occurrence of any autoantibody in T1D patients (60.3%) was significantly higher than that of T2D patients (18.5%) (P-lt;-.001). There was a statistically different association with family history of diabetes among the autoantibody positive versus autoantibody negative patients with T1D (P-lt;-.01). Our results confirmed the presence of GADAs and ICA in T1D patients in Iran, though roughly at a lower prevalence than that reported for Caucasian T1D patients, but very similar to other non-Caucasian ethnic populations.